Skeletal muscle radiodensity is prognostic for survival in patients with advanced non-small cell lung cancer

Clinical Nutrition

Volumn 35, Issue 6, 2016, Pages 1386-1393

  Sjøblom, Bjørg ^a,b   Grønberg, Bjørn H ^c,h   Wentzel Larsen, Tore ^d,e,f   Baracos, Vickie E ^g   Hjermstad, Marianne J ^b,h   Aass, Nina ^b,i   Bremnes, Roy M ^j,k   Fløtten, Øystein ^f   Bye, Asta ^b,l   Jordhøy, Marit ^a,i  

^a INNLANDET HOSPITAL TRUST   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^d Norwegian Centre of Violence and Traumatic Stress Studies   (Norway)

^e ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^f HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^g UNIVERSITY OF ALBERTA   (Canada)

^h NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

ⁱ UNIVERSITY OF OSLO   (Norway)

^j UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^k UNIVERSITY OF TROMSØ   (Norway)

^l OSLO METROPOLITAN UNIVERSITY   (Norway)

more..

Author keywords

Body composition; Non small cell lung cancer; Prognostic factor; Radiodensity; Sarcopenia; Survival

Indexed keywords

CARBOPLATIN; GEMCITABINE; NAVELBINE; PEMETREXED;

ADVANCED CANCER; AGED; ARTICLE; BODY COMPOSITION; BODY MASS; BONE DENSITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE MASS; MUSCULOSKELETAL SYSTEM EXAMINATION; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIMARY MEDICAL CARE; QUALITY OF LIFE; RADIOLOGICAL PARAMETERS; RANDOMIZED CONTROLLED TRIAL; SKELETAL MUSCLE; SKELETAL MUSCLE INDEX; SKELETAL MUSCLE RADIODENSITY; THIRD LUMBAR VERTEBRA; CACHEXIA; COMPLICATION; IMAGE PROCESSING; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SARCOPENIA; ULTRASTRUCTURE; X-RAY COMPUTED TOMOGRAPHY;

AGED; BODY MASS INDEX; CACHEXIA; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; PROGNOSIS; SARCOPENIA; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84963819076     PISSN: 02615614     EISSN: 15321983     Source Type: Journal    
DOI: 10.1016/j.clnu.2016.03.010     Document Type: Article

References (38)

1. [1] Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., Forman, D., Global cancer statistics. CA Cancer J Clin 61:2 (2011 Mar–Apr), 69–90 PubMed PMID: 21296855. Epub 2011/02/08.
2. [2] Morgensztern, D., Ng, S.H., Gao, F., Govindan, R., Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. J Thorac Oncol 5:1 (2010 Jan), 29–33 PubMed PMID: 19952801. Epub 2009/12/03.
3. [3] Helbekkmo, N., Sundstrom, S.H., Aasebo, U., Brunsvig, P.F., von Plessen, C., Hjelde, H.H., et al. Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br J Cancer 97:3 (2007 Aug 6), 283–289 PubMed PMID: 17595658. Pubmed Central PMCID: PMC2360329. Epub 2007/06/28.
4. [4] Gronberg, B.H., Bremnes, R.M., Flotten, O., Amundsen, T., Brunsvig, P.F., Hjelde, H.H., et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 27:19 (2009 Jul 1), 3217–3224 PubMed PMID: 19433683. Epub 2009/05/13.
5. [5] Flotten, O., Gronberg, B.H., Bremnes, R., Amundsen, T., Sundstrom, S., Rolke, H., et al. Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group. Br J Cancer 107:3 (2012 Jul 24), 442–447 PubMed PMID: 22759880. Pubmed Central PMCID: PMC3405221. Epub 2012/07/05.
6. [6] Cuyun Carter, G., Barrett, A.M., Kaye, J.A., Liepa, A.M., Winfree, K.B., John, W.J., A comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small-cell lung cancer. Cancer Manag Res 6 (2014), 437–449 PubMed PMID: 25364274. Pubmed Central PMCID: PMC4211870. Epub 2014/11/05.
7. [7] Fearon, K.C., Cancer cachexia: developing multimodal therapy for a multidimensional problem. Eur J Cancer 44:8 (2008 May), 1124–1132 PubMed PMID: 18375115. Epub 2008/04/01.
8. [8] Baracos, V.E., Reiman, T., Mourtzakis, M., Gioulbasanis, I., Antoun, S., Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis. Am J Clin Nutr 91:4 (2010 Apr), 1133S–1137S PubMed PMID: 20164322. Epub 2010/02/19.
9. [9] Muscaritoli, M., Anker, S.D., Argiles, J., Aversa, Z., Bauer, J.M., Biolo, G., et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) “cachexia-anorexia in chronic wasting diseases” and “nutrition in geriatrics”. Clin Nutr 29:2 (2010 Apr), 154–159 PubMed PMID: 20060626. Epub 2010/01/12.
10. [10] Kazemi-Bajestani, S.M., Mazurak, V.C., Baracos, V., Computed tomography-defined muscle and fat wasting are associated with cancer clinical outcomes. Semin Cell Dev Biol, 2015 Sep 3 PubMed PMID: 26343952. Epub 2015/09/08.
11. [11] Jung, H.W., Kim, J.W., Kim, J.Y., Kim, S.W., Yang, H.K., Lee, J.W., et al. Effect of muscle mass on toxicity and survival in patients with colon cancer undergoing adjuvant chemotherapy. Support Care Cancer 23:3 (2015 Mar), 687–694 PubMed PMID: 25163434. Epub 2014/08/29.
12. [12] Fujiwara, N., Nakagawa, H., Kudo, Y., Tateishi, R., Taguri, M., Watadani, T., et al. Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma. J Hepatol 63:1 (2015 Jul), 131–140 PubMed PMID: 25724366. Epub 2015/03/01.
13. [13] Martin, L., Birdsell, L., Macdonald, N., Reiman, T., Clandinin, M.T., McCargar, L.J., et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 31:12 (2013 Apr 20), 1539–1547 PubMed PMID: 23530101. Epub 2013/03/27.
14. [14] Prado, C.M., Lieffers, J.R., McCargar, L.J., Reiman, T., Sawyer, M.B., Martin, L., et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 9:7 (2008 Jul), 629–635 PubMed PMID: 18539529. Epub 2008/06/10.
15. [15] van Vledder, M.G., Levolger, S., Ayez, N., Verhoef, C., Tran, T.C., Ijzermans, J.N., Body composition and outcome in patients undergoing resection of colorectal liver metastases. Br J Surg 99:4 (2012 Apr), 550–557 PubMed PMID: 22246799. Epub 2012/01/17.
16. [16] Lanic, H., Kraut-Tauzia, J., Modzelewski, R., Clatot, F., Mareschal, S., Picquenot, J.M., et al. Sarcopenia is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Leuk Lymphoma 55:4 (2014 Apr), 817–823 PubMed PMID: 23781925. Epub 2013/06/21.
17. [17] Cruz-Jentoft, A.J., Baeyens, J.P., Bauer, J.M., Boirie, Y., Cederholm, T., Landi, F., et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing 39:4 (2010 Jul), 412–423 PubMed PMID: 20392703. Pubmed Central PMCID: PMC2886201. Epub 2010/04/16.
18. [18] Fragala, M.S., Kenny, A.M., Kuchel, G.A., Muscle quality in aging: a multi-dimensional approach to muscle functioning with applications for treatment. Sports Med 45:5 (2015 May), 641–658 PubMed PMID: 25655372. Epub 2015/02/07.
19. [19] Aubrey, J., Esfandiari, N., Baracos, V.E., Buteau, F.A., Frenette, J., Putman, C.T., et al. Measurement of skeletal muscle radiation attenuation and basis of its biological variation. Acta Physiol Oxf Engl 210:3 (2014 Mar), 489–497 PubMed PMID: 24393306. Pubmed Central PMCID: PMC4309522. Epub 2014/01/08.
20. [20] Sabel, M.S., Lee, J., Cai, S., Englesbe, M.J., Holcombe, S., Wang, S., Sarcopenia as a prognostic factor among patients with stage III melanoma. Ann Surg Oncol 18:13 (2011 Dec), 3579–3585 PubMed PMID: 21822551. Epub 2011/08/09.
21. [21] Miller, B.S., Ignatoski, K.M., Daignault, S., Lindland, C., Doherty, M., Gauger, P.G., et al. Worsening central sarcopenia and increasing intra-abdominal fat correlate with decreased survival in patients with adrenocortical carcinoma. World J Surg 36:7 (2012 Jul), 1509–1516 PubMed PMID: 22526034. Epub 2012/04/25.
22. [22] Antoun, S., Lanoy, E., Iacovelli, R., Albiges-Sauvin, L., Loriot, Y., Merad-Taoufik, M., et al. Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies. Cancer 119:18 (2013 Sep 15), 3377–3384 PubMed PMID: 23801109. Epub 2013/06/27.
23. [23] Aaronson, N.K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N.J., et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:5 (1993 Mar 3), 365–376 PubMed PMID: 8433390. Epub 1993/03/03.
24. [24] Shen, W., Punyanitya, M., Wang, Z., Gallagher, D., St-Onge, M.P., Albu, J., et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol (Bethesda, Md 1985) 97:6 (2004 Dec), 2333–2338 PubMed PMID: 15310748. Epub 2004/08/18.
25. [25] Altman, D.G., McShane, L.M., Sauerbrei, W., Taube, S.E., Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. PLoS Med, 9(5), 2012, e1001216 PubMed PMID: 22675273. Pubmed Central PMCID: PMC3362085. Epub 2012/06/08.
26. [26] Rollins, K.E., Tewari, N., Ackner, A., Awwad, A., Madhusudan, S., Macdonald, I.A., et al. The impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangiocarcinoma. Clin Nutr 35:5 (2016), 1103–1109.
27. [27] Goodpaster, B.H., Kelley, D.E., Thaete, F.L., He, J., Ross, R., Skeletal muscle attenuation determined by computed tomography is associated with skeletal muscle lipid content. J Appl Physiol (Bethesda, Md 1985) 89:1 (2000 Jul), 104–110 PubMed PMID: 10904041. Epub 2000/07/25.
28. [28] Miljkovic, I., Zmuda, J.M., Epidemiology of myosteatosis. Curr Opin Clin Nutr Metab Care 13:3 (2010 May), 260–264 PubMed PMID: 20179586. Pubmed Central PMCID: PMC2872135. Epub 2010/02/25.
29. [29] Stephens, N.A., Skipworth, R.J., Macdonald, A.J., Greig, C.A., Ross, J.A., Fearon, K.C., Intramyocellular lipid droplets increase with progression of cachexia in cancer patients. J Cachexia Sarcopenia Muscle 2:2 (2011 Jun), 111–117 PubMed PMID: 21766057. Pubmed Central PMCID: PMC3117997. Epub 2011/07/19.
30. [30] Honors, M.A., Kinzig, K.P., The role of insulin resistance in the development of muscle wasting during cancer cachexia. J Cachexia Sarcopenia Muscle 3:1 (2012 Mar), 5–11 PubMed PMID: 22450024. Pubmed Central PMCID: PMC3302982. Epub 2012/03/28.
31. [31] Malietzis, G., Johns, N., Al-Hassi, H.O., Knight, S.C., Kennedy, R.H., Fearon, K.C., et al. Low muscularity and myosteatosis is related to the host systemic inflammatory response in patients undergoing surgery for colorectal cancer. Ann Surg 263:2 (2016 Feb), 320–325 PubMed PMID: 25643288. Epub 2015/02/03.
32. [32] Clarke, S.J., Chua, W., Moore, M., Kao, S., Phan, V., Tan, C., et al. Use of inflammatory markers to guide cancer treatment. Clin Pharmacol Ther 90:3 (2011 Sep), 475–478 PubMed PMID: 21775983. Epub 2011/07/22.
33. [33] Tan, B.H., Birdsell, L.A., Martin, L., Baracos, V.E., Fearon, K.C., Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res 15:22 (2009 Nov 15), 6973–6979 PubMed PMID: 19887488. Epub 2009/11/06.
34. [34] Dodson, R.M., Firoozmand, A., Hyder, O., Tacher, V., Cosgrove, D.P., Bhagat, N., et al. Impact of sarcopenia on outcomes following intra-arterial therapy of hepatic malignancies. J Gastrointest Surg 17:12 (2013 Dec), 2123–2132 PubMed PMID: 24065364. Pubmed Central PMCID: PMC3982291. Epub 2013/09/26.
35. [35] Miyamoto, Y., Baba, Y., Sakamoto, Y., Ohuchi, M., Tokunaga, R., Kurashige, J., et al. Sarcopenia is a negative prognostic factor after curative resection of colorectal cancer. Ann Surg Oncol 22:8 (2015 Aug), 2663–2668 PubMed PMID: 25564158. Epub 2015/01/08.
36. [36] Miyamoto, Y., Baba, Y., Sakamoto, Y., Ohuchi, M., Tokunaga, R., Kurashige, J., et al. Negative impact of skeletal muscle loss after systemic chemotherapy in patients with unresectable colorectal cancer. PLoS One, 10(6), 2015, e0129742 PubMed PMID: 26069972. Pubmed Central PMCID: PMC4466562. Epub 2015/06/13.
37. [37] Dalal, S., Hui, D., Bidaut, L., Lem, K., Del Fabbro, E., Crane, C., et al. Relationships among body mass index, longitudinal body composition alterations, and survival in patients with locally advanced pancreatic cancer receiving chemoradiation: a pilot study. J Pain Symptom Manag 44:2 (2012 Aug), 181–191 PubMed PMID: 22695045. Pubmed Central PMCID: PMC3990439. Epub 2012/06/15.
38. [38] Wakelee, H.A., Wang, W., Schiller, J.H., Langer, C.J., Sandler, A.B., Belani, C.P., et al. Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594. J Thorac Oncol 1:5 (2006 Jun), 441–446 PubMed PMID: 17409897. Epub 2007/04/06.